HBsAg seroclearance in chronic hepatitis b: Implications for hepatocellular carcinoma

Journal of Clinical Gastroenterology

Volumn 45, Issue 1, 2011, Pages 64-68

  Kim, Ji Hoon ^a   Lee, Young Sun ^a   Lee, Hyun Jung ^a   Yoon, Eileen ^a   Jung, Young Kul ^a   Jong, Eun Suck ^a   Lee, Beom Jae ^a   Seo, Yeon Seok ^a   Yim, Hyung Joon ^a   Yeon, Jong Eun ^a   Park, Jong Jae ^a   Kim, Jae Seon ^a   Bak, Young Tae ^a   Byun, Kwan Soo ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

chronic hepatitis B; hepatitis B virus surface antigen; hepatocellular carcinoma; seroclearance

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALBUMIN; BILIRUBIN; HEPATITIS B SURFACE ANTIGEN; INTERFERON; LAMIVUDINE; VIRUS DNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CANCER INCIDENCE; CANCER RISK; CHRONIC HEPATITIS; DISEASE DURATION; DISEASE SURVEILLANCE; FAMILY HISTORY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SEROCLEARANCE; SEROLOGY; SMOKING;

ADULT; AGE FACTORS; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 78650953491     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181dd558c     Document Type: Article

References (28)

1. European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227-242.
2. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007; 45:507-539.
3. Chan HL, Wong VW, Tse AM, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol. 2007;5:1462-1468.
4. Da Silva LC, Madruga CL, Carrilho FJ, et al. Spontaneous hepatitis B surface antigen clearance in a long-term follow-up study of patients with chronic type B hepatitis. Lack of correlation with hepatitis C and D virus superinfection. J Gastroenterol. 1996;31:696-701.
5. Fattovich G, Giustina G, Sanchez-Tapias J, et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European concerted action on viral hepatitis. Am J Gastroenterol. 1998; 93:896-900.
6. Alward WL, McMahon BJ, Hall DB et al. The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. J Infect Dis. 1985;151:604-609.
7. Hsu HY, Chang MH, Lee CY, et al. Spontaneous loss of HBsAg in children with chronic hepatitis B virus infection. Hepatology. 1992;15:382-386.
8. Liaw YF, Sheen IS, Chen TJ, et al. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology. 1991;13:627-631.
9. McMahon BJ, Alberts SR, Wainwright RB, et al. Hepatitis B b-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med. 1990;150:1051-1054.
10. Sampliner RE, Hamilton FA, Iseri OA et al. The liver histology and frequency of clearance of the hepatitis B surface antigen (HBsAg) in chronic carriers. Am J Med Sci. 1979;277:17-22.
11. Wu TT, Hsu HC, Chen DS, et al. Clearance of hepatitis B surface antigen (HBsAg) after surgical resection of hepatocellular carcinoma. J Hepatol. 1987;4:45-51.
12. Perrillo RP, Brunt EM. Hepatic histologic and immunohistochemical changes in chronic hepatitis B after prolonged clearance of hepatitis B e antigen and hepatitis B surface antigen. Ann Inter Med. 1991;115:113-115.
13. Adachi H, Kaneko S, Matsushita E, et al. Clearance of HBsAg in seven patients with chronic hepatitis B. Hepatology. 1992;16: 1334-1337.
14. Brechot C, Degos F, Lugassy C, et al. Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. New Engl J Med. 1985;312:270-276.
15. Huo TI, Wu JC, Lee PC, et al. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology. 1998;28:231-236.
16. Arase Y, Ikeda K, Suzuki F, et al. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med. 2006;119:71e9-71e16.
17. Chen YC, Sheen IS, Chu CM, et al. Prognosis following spontaneous B seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology. 2002; 123:1084-1089.
18. Yuen MF, Wong DK, Fung J, et al. HBsAg seroclearance in chronic hepatitis B in asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology. 2008;135: 1192-1199.
19. Ding X, Mizokami M, Yao G, et al. Hepatitis B virus genotype distribution among chronic hepatitis B virus carriers in shanghai, china. Intervirology. 2001;44:43-47. (Pubitemid 32172943)
20. Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology. 2002;122: 1756-1762.
21. Sumi H, Yokosuka O, Seki N, et al. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology. 2003;37:19-26.
22. Yuen MF, Wong DK, Sablon E, et al. HBsAg seroclearance in chronic hepatitis B in the chinese: virological, histological, and clinical aspects. Hepatology. 2004;39:1694-1701.
23. Kao JH. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol. 2002; 17:643-650.
24. Kim JH, Lee SJ, Joo MK, et al. Durability of antiviral response in HBeAg-positive chronic hepatitis B patients who maintained virologic response for one year after lamivudine discontinuation. Dig Dis Sci. 2009;54:1572-1577.
25. Park JW. Practice guideline for diagnosis and treatment of hepatocellular carcinoma. Korean J Hepatol. 2004;10:88-98.
26. Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology. 2007;45:1187-1192.
27. Komori M, Yuki N, Nagaoka T, et al. Long-term clinical impact of occult hepatitis B virus infection in chronic hepatitis B patients. J Hepatol. 2001;35:798-804.
28. Ahn SH, Park YN, Park JY, et al. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol. 2005;42:188-194.